What Alkyon Therapeutics does

Alkyon Therapeutics is a private, formation-stage biotechnology company founded in 2024 and headquartered in San Diego, California. According to its firmographic profile, the company develops radioligand therapies (RLTs) targeting solid tumor cancers using precision-targeted radiopharmaceuticals. The company's public surface is limited to a landing page (alkyontx.com) bearing only the company name and the tagline "Precision in every strike"; no pipeline assets, lead indications, target antigens, radioisotope selection, development stage, mechanism specifics, or scientific founders are disclosed in the available source material.

The company operates with a headcount of 1-10 employees and has not publicly disclosed any products, services, partnerships, intellectual property, management roster, scientific advisory board, manufacturing capabilities, clinical programs, or funding history. No revenue model, pricing structure, go-to-market approach, customer base, or distribution channels are articulated in the input data; the operating geography is implied to be the United States based on incorporation in San Diego, with no global footprint claims. The firmographic profile and product/technology fields are otherwise empty or marked as undetermined from available sources.

Given the absence of disclosed funding, named leadership, pipeline assets, regulatory milestones, or operational infrastructure, Alkyon Therapeutics appears to be in a pre-seed or formation phase. The radioligand therapy modality is structurally capital-intensive — requiring isotope supply chain access, GMP radiopharmaceutical manufacturing, specialized handling facilities, and substantial clinical development capital — none of which is evidenced in the available data for this specific company.

Name

Alkyon Therapeutics

Website

https://alkyontx.com

Company type

Private

Founded year

2024

Headcount range

1–10 employees

Short description

Alkyon Therapeutics is a private, formation-stage San Diego-based biotechnology company founded in 2024 that claims to develop precision-targeted radioligand therapies for solid tumor cancers, though no pipeline, leadership, or funding details are publicly disclosed.

Ownership category

akta.pro rank

Product category

Radiopharmaceuticals / Radioligand Therapeutics

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

akta.pro secondary industry

Medical Oncology (HLAKAFAB)

Keywords

• Radioligand therapy
• Radiopharmaceutical development
• Precision oncology
• Solid tumor therapy
• Targeted cancer treatment

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Others

Core offering

Alkyon Therapeutics develops precision-targeted radioligand therapies designed to treat solid tumor cancers. The company focuses on engineering radiopharmaceuticals that selectively deliver therapeutic radiation to malignant tissue. As a 2024-founded private biotech, it operates in the discovery and preclinical-to-early-development phase of oncology therapeutics.

Product overview

Unable to determine product/service offerings from the available source content. The landing page provides only the company name and tagline without detailing any specific products, services, or portfolio architecture.

Differentiator

Problem solved

Functional benefit

Products and services

• Radioligand therapy pipeline (solid tumor cancers) Discovery-stage radioligand therapeutics designed to deliver targeted radiation to solid tumor cells. Targeted indications, mechanism specifics, and development stage are not publicly disclosed.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves2 records

Expansion highlights2 records

Broad incumbents

• RayzeBio (Bristol Myers Squibb): RayzeBio, acquired by BMS for ~$4.1B in 2024, developed actinium-225-based radiopharmaceuticals for solid tumors. Its acquisition sets the most recent valuation benchmark for solid-tumor RLT platforms and frames the type of strategic exit Alkyon could pursue.
• Novartis: Novartis pioneered the modern radioligand therapy category with Lutathera and Pluvicto and continues to expand its solid tumor RLT pipeline. Broad incumbent — not a focused radiopharma — but the dominant player defining the modality that Alkyon is entering.
• Bayer (Xofigo, curium pipeline): Bayer markets Xofigo (radium-223) in oncology and has invested in targeted radionuclide therapy through its curium platform partnership. A broad incumbent with multiple radiopharmaceutical programs across solid tumor indications.
• POINT Biopharma (Eli Lilly): POINT developed Lu-177 and actinium-based radioligand therapies for solid tumors and was acquired by Lilly for ~$1.4B in 2023. Another representative solid-tumor RLT platform exit that defines the comparable set for Alkyon.
• Fusion Pharmaceuticals (AstraZeneca): Fusion was an Ontario-based radioconjugate developer focused on actinium-225 solid tumor programs, acquired by AstraZeneca for ~$2.4B in 2024. A near-direct analog for a small solid-tumor radioligand platform being absorbed by big pharma.

Direct peers

• Lantheus Holdings: Lantheus is a leading radiopharmaceutical-focused company with commercial diagnostics and an expanding therapeutic radioligand pipeline including PSMA and other solid tumor programs. Closest direct peer to Alkyon in therapeutic radiopharmaceuticals, though at commercial scale.
• Ariceum Therapeutics: Ariceum is a private radiopharmaceutical developer focused on targeted radionuclide therapies for solid tumors and hematologic malignancies. Comparable modality, indication focus, and stage to Alkyon as a private RLT-focused biotech.
• Telix Pharmaceuticals: Telix is a publicly traded radiopharmaceutical company developing targeted theranostic and therapeutic agents for cancer, including solid tumor indications such as renal and prostate cancer. Directly comparable to Alkyon as a dedicated radioligand/radiopharmaceutical developer, but with approved products, GMP manufacturing, and full clinical pipelines.
• ITM Isotope Technology Munich: ITM is a Germany-based radiopharmaceutical company developing therapeutic and diagnostic radioisotope products for cancer, including solid tumor RLT programs. Comparable as a dedicated therapeutic radiopharma developer with infrastructure assets that Alkyon currently lacks.
• Aktis Oncology: Aktis Oncology is a private, well-funded radiopharmaceutical company developing miniprotein-based targeted radioconjugates for solid tumors. Closest stage-comparable and modality-aligned private peer to Alkyon, with disclosed Series A/B funding and named leadership.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat1 record

Key risks4 records

Key highlights3 records

Customer concentration

• LinkedInlinkedin.com/company/alkyon-therapeutics-alkyontx

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alkyon Therapeutics